Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.
Checked against the public recordLast updated Jan 22, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- West Virginia University
- Interventions being studied
- Radiation: Image Guided Stereotactic Ablative Radiotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Non-Small Cell Lung Cancer * T2N0M0 or T3(PL3)N0M0 or Locally recurrent ≤ 7 cm * Surgically inoperable * ECOG Performance 0-2 Exclusion Criteria: * Pacemaker on the same side of the tumor * Pregnant * Infection that requires IV antibiotics * Concomitant or adjuvant anti-neoplastic chemotherapy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- West Virginia University Hospitals Mary Babb Randolph Cancer CenterMorgantown, West Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 22, 2021. Always confirm current availability with the study team.